- AI
- Arbitration
- Asia
- Automobile
- Bangladesh
- Banking
- Biodiversity
- Biological Inventions
- bLAWgathon
- Brand Valuation
- Business
- Celebrity Rights
- Company Act
- Company Law
- Competition Law
- Constitutional Law
- Consumer Law
- Consumer Protection Authority
- Copyright
- Copyright Infringement
- Copyright Litigation
- Corporate Law
- Counterfeiting
- Covid
- Design
- Digital Media
- Digital Right Management
- Dispute
- Educational Conferences/ Seminar
- Environment Law Practice
- ESIC Act
- EX-Parte
- Farmer Right
- Fashion Law
- FDI
- FERs
- Foreign filing license
- Foreign Law
- Gaming Industry
- GDPR
- Geographical Indication (GI)
- GIg Economy
- Hi Tech Patent Commercialisation
- Hi Tech Patent Litigation
- IBC
- India
- Indonesia
- Intellectual Property
- Intellectual Property Protection
- IP Commercialization
- IP Licensing
- IP Litigation
- IP Practice in India
- IPAB
- IPAB Decisions
- IT Act
- IVF technique
- Judiciary
- Khadi Industries
- labour Law
- Legal Case
- Legal Issues
- Lex Causae
- Licensing
- Live-in relationships
- Lok Sabha Bill
- Marriage Act
- Maternity Benefit Act
- Media & Entertainment Law
- Mediation Act
- Member of Parliament
- Mergers & Acquisition
- Myanmar
- NCLT
- NEPAL
- News & Updates
- Non-Disclosure Agreement
- Online Gaming
- Patent Act
- Patent Commercialisation
- Patent Fess
- Patent Filing
- patent infringement
- Patent Licensing
- Patent Litigation
- Patent Marketing
- Patent Opposition
- Patent Rule Amendment
- Patents
- Personality rights
- pharma
- Pharma- biotech- Patent Commercialisation
- Pharma/Biotech Patent Litigations
- Pollution
- Posh Act
- Protection of SMEs
- RERA
- Section 3(D)
- Signapore
- Social Media
- Sports Law
- Stamp Duty
- Stock Exchange
- Surrogacy in India
- TAX
- Technology
- Telecom Law
- Telecommunications
- Thailand
- Trademark
- Trademark Infringement
- Trademark Litigation
- Traditional Knowledge
- UAE
- Uncategorized
- USPTO
- Vietnam
- WIPO
Two Day International Symposium On Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios
IIPRD (Institute of Intellectual Property Research & Development) is happy to announce its International Symposium on Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios. Presentation of all important patent issues such as identification of potential inventions, Biosimilar Legislation, preparation of claim sets, prosecution and examination practices, drafting of responses of Office Actions, ANDA Litigation, … Continue reading Two Day International Symposium On Strategies for Managing Pharmaceutical, Biotechnology & Chemical Patent Portfolios
Read more »One Day Symposium On Advanced Patent Issues Related To Software, Electronics, Telecommunication Business Methods & Network Computing With Focus on US, EP, and Indian Scenario
IIPRD (Institute of Intellectual Property Research & Development) is happy to announce its International Symposium on Advanced Software, Electronics, and Business Method Patent issues. Presentation of all important Patent Issues relating to Prosecution and Enforcement Strategies, Identification of potential inventions, Types of claims allowed in each geography, and their relevance to the broadness of claims, … Continue reading One Day Symposium On Advanced Patent Issues Related To Software, Electronics, Telecommunication Business Methods & Network Computing With Focus on US, EP, and Indian Scenario
Read more »Inventors, All Technologies Aren’t Worth Billions
31st July, 2011 - 6:23 pm
Categories:
Hi Tech Patent Commercialisation
Patent Commercialisation
Pharma- biotech- Patent Commercialisation
0 Comments
Working in the IP/Technology Commercialization and Out-Licensing domain makes you assess and evaluate commercial viability of numerous IP backed inventions across technology domains. Apart from learning about and assessing new technologies, we also tend to learn quite of lot about Inventors mindset, specifically about their perspective of their own inventions. This article relates to our … Continue reading Inventors, All Technologies Aren’t Worth Billions
Read more »